These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26447590)

  • 1. Nanotherapeutics with anthracyclines: methods of determination and quantification of anthracyclines in biological samples.
    Koziolova E; Janouskova O; Chytil P; Studenovsky M; Kostka L; Etrych T
    Physiol Res; 2015; 64(Suppl 1):S1-10. PubMed ID: 26447590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular fate of polymer therapeutics investigated by fluorescence lifetime imaging and fluorescence pattern analysis.
    Panek J; Koziolova E; Stepanek P; Etrych T; Janouskova O
    Physiol Res; 2016 Oct; 65(Suppl 2):S217-S224. PubMed ID: 27762587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of experimental conditions for the preparative displacement chromatography of antitumor anthracycline antibiotics on carboxylic sorbents.
    Toshchevikova AY; Ezhova NM; Pisarev OA
    J Chromatogr A; 2003 Jul; 1006(1-2):121-6. PubMed ID: 12938880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modern imaging techniques for anthracycline cytostatics -  review of the literature].
    Blažková I; Ryvolová M; Křížková S; Jílková E; Kopel P; Eckschlager T; Stiborová M; Adam V; Kizek R
    Klin Onkol; 2013; 26(4):239-44. PubMed ID: 23961853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration.
    Whitaker G; Lillquist A; Pasas SA; O'Connor R; Regan F; Lunte CE; Smyth MR
    J Sep Sci; 2008 Jun; 31(10):1828-33. PubMed ID: 18461567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of liposomal anthracyclines in breast cancer.
    Lorusso V; Manzione L; Silvestris N
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi70-3. PubMed ID: 17591837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic routes to nanomaterials containing anthracyclines: noncovalent systems.
    Piorecka K; Kurjata J; Stanczyk M; Stanczyk WA
    Biomater Sci; 2018 Sep; 6(10):2552-2565. PubMed ID: 30140825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
    Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
    Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
    Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
    Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracyclines in the treatment of gynecologic malignancies.
    Maluf FC; Spriggs D
    Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracyclines in early-stage breast cancer: is it the end of an era?
    Robson D; Verma S
    Oncologist; 2009 Oct; 14(10):950-8. PubMed ID: 19561291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Jasra S; Anampa J
    Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometric approaches for the identification of anthracycline analogs produced by actinobacteria.
    Bauermeister A; Zucchi TD; Moraes LA
    J Mass Spectrom; 2016 Jun; 51(6):437-45. PubMed ID: 27270867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer.
    Taatjes DJ; Fenick DJ; Gaudiano G; Koch TH
    Curr Pharm Des; 1998 Jun; 4(3):203-18. PubMed ID: 10197040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
    Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
    Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: a comparative study of the efficacy of anthracyclines and non-anthracyclines.
    Chen WW; Chang DY; Huang SM; Lin CH; Hsu C; Lin MH; Huang CS; Lu YS; Cheng AL
    Breast; 2013 Dec; 22(6):1148-54. PubMed ID: 23968865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Control of the myocardial pump function during cytostatic treatment with anthracycline].
    Hesse B; Mouridsen HT; Schaadt BK; Meyer C
    Ugeskr Laeger; 1996 Aug; 158(33):4628-30. PubMed ID: 8760518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.